bearish
China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine
367 Views25 Jun 2023 09:29
Results of National TCM VBP were released, involving some big varieties. CDE changes game rule on drug approva. Companies has to change clinical strategy timely. We analyzed key points of Hua Medicine
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Jul.14)-TCM Demand Switch, 8% Benchmark Growth Rate, GLP-1 Change Game Rule16 Jul 2023
- Moderna Inc (MRNA US) - What Would Happen After Moderna Enters China?12 Jul 2023
- China Healthcare Weekly (Jul.7) - New NRDL Negotiation Rules, Assisted Reproduction Payment, Kintor09 Jul 2023
- China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine25 Jun 2023
- Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises21 Jun 2023
- China Healthcare Weekly (Jun.16)- 9th National VBP Update, “Noise” of Consumption Upgrading, ChatGPT18 Jun 2023
- Wuxi Biologics (2269.HK) - Some New Business Updates and the Outlook08 Jun 2023
x